Holen Sie sich die Stockscreener-App
2.06
0.00%
0.00
Handel nachbörslich:
2.06
Schlusskurs vom Vortag:
$2.06
Offen:
$2.06
24-Stunden-Volumen:
3,409
Relative Volume:
0.09
Marktkapitalisierung:
$23.84M
Einnahmen:
$3.35M
Nettoeinkommen (Verlust:
$86,000
KGV:
133.77
EPS:
0.0154
Netto-Cashflow:
$2.67M
1W Leistung:
-0.48%
1M Leistung:
+0.98%
6M Leistung:
-10.43%
1J Leistung:
+90.74%
1-Tages-Spanne:
$2.04
$2.0699
1-Wochen-Bereich:
$2.00
$2.0699
52-Wochen-Spanne:
$0.99
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.06 | 23.84M | 3.35M | 86,000 | 2.67M | 0.0154 |
TAK
Takeda Pharmaceutical Co Adr
|
18.18 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
10.00 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.34 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
77.73 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
513.12 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD - TradingView
TherapeuticsMD(TXMD) Stock Options Chain | Quotes & News - Moomoo
TherapeuticsMD Company Profile & Introduction - Moomoo
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD, Inc. Revenue Breakdown – DUS:29TA - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
TherapeuticsMD (TXMD) Holds Steady at $2.08 as Traders Eye Key Support and ResistanceBull Flag - vinanet.vn
TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year - clinicaltrialvanguard.com
TherapeuticsMD: Q2 Earnings Snapshot - AOL.com
TherapeuticsMD Q2 Net Income From Cont Ops US - Moomoo
TherapeuticsMD Q2 EPS drops 80% to $0.01 on sales slide - scanx.trade
Is TherapeuticsMD Inc (TXMD) Positioned for Growth After Q2 Earn - GuruFocus
TherapeuticsMD Q2 Results and Strategic Alternatives Review - TipRanks
TherapeuticsMD, Inc. Q2 2026: Revenue $869K, EPS $0.01— 10-Q Summary - TradingView
TherapeuticsMD Q2 license revenue falls; continues to evaluate strategic alternatives - TradingView
TherapeuticsMD Q2 2026 License Revenue Falls to $869000 - Quiver Quantitative
TherapeuticsMD | 10-Q: Q2 2026 Earnings Report - Moomoo
TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline - TradingKey
TXMD: Q2 2026 saw lower net income and license revenue, with strategic alternatives under evaluation - TradingView
TherapeuticsMD (TXMD) posts Q2 2026 update and weighs strategic alternatives - Stock Titan
TherapeuticsMD to Recognize About $365K IMVEXXY Milestone in Q3 - Stock Titan
TherapeuticsMD, Inc. (29TA.SG) stock price, news, quote and history - Yahoo Finance Australia
TXMD Q3 2023 Earnings: Wider-Than-Expected Loss of -$0.13 Weighs on SharesEarnings Per Share - vinanet.vn
Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock - Stock Titan
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
TherapeuticsMD, Inc. (29TA.SG) Stock Price, News, Quote & History - Yahoo! Finance Canada
TherapeuticsMD (TXMD) Holds Steady at $2.03 as Trading Range NarrowsVolume Rate Change - dars.gov.et
TXMD|TherapeuticsMD Inc|Price:2.090|Chg%:+0.060 - TradingKey
TherapeuticsMD Inc. (TXMD) Slips Further: Key Support Levels Under PressurePCR Spike - dars.gov.et
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD, Inc. Revenue Breakdown – SWB:29TA - TradingView
TherapeuticsMD Inc (TXMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TherapeuticsMD Inc (TXMD) Cash Flow - TradingKey
TherapeuticsMD (TXMD) Holds Steady Near Key Support With Slight UptickCall Spread Alert - dars.gov.et
TherapeuticsMD Inc (TXMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TherapeuticsMD Inc (TXMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
TherapeuticsMD, Inc. Revenue Breakdown – MUN:29TA - TradingView
TherapeuticsMD Inc (TXMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TherapeuticsMD Inc (TXMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.060| - TradingKey
TXMD|TherapeuticsMD Inc|Price:2.070| - TradingKey
TherapeuticsMD (TXMD) Holds Steady at $2.06 as Consolidation ContinuesPut Support - dars.gov.et
TherapeuticsMD Inc (TXMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TXMD Q3 2023 Earnings: Significant EPS Miss Amid Ongoing ChallengesEarnings Call Highlights - DonanımHaber
TherapeuticsMD (TXMD) News Flow - Moomoo
TherapeuticsMD (TXMD) Edges Higher, Consolidating Near $2.00TRIN Signal - dars.gov.et
TherapeuticsMD (TXMD) Slips 3.32% as Stock Tests Key Support Near $2.00Long Setup Ideas - dars.gov.et
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):